altRX vs Push Health
altRX costs $801 less a month, and both sell semaglutide.
Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more
If you are choosing between altRX and Push Health, the first difference is cost: altRX is $801 a month cheaper at the entry price. Both prescribe semaglutide, so moving from one to the other would not change your drug. altRX leads our six-part score, 6.7 to 5.6. One of the two has an FDA warning letter on record, covered below.
altRX vs Push Health price
altRX is the cheaper way in: $149 a month against $950 a month at Push Health. That is $801 less each month (84% lower), or about $9,612 over a year of treatment.
Drug by drug: Semaglutide is cheaper at altRX ($149 a month vs $950 a month).
Medications and formats
Both sell semaglutide; only altRX lists tirzepatide.
On format, altRX prices compounded injections and brand-name pens, while Push Health prices brand-name pens.
Where each one treats patients
Neither altRX nor Push Health publishes the states it serves, so enter your state at the very start of each sign-up.
Pricing
altRX
Push Health
Ozempic / brand
What each price covers
altRX's price also covers the clinician visit, the medication itself and shipping, which Push Health does not claim.
altRX is silent on lab work and coaching.
Push Health does not say what its price includes.
That matters most for the drug: unless Push Health confirms otherwise, budget for medication on top of its listed price.
altRX
Covered by the monthly price
Medication
In the price
Clinician visits
In the price
Shipping
In the price
Lab work
Not stated
Coaching
Not stated
Push Health
Inclusions not disclosed.
Where each one scores higher
Overall, altRX scores 6.7 and Push Health 5.6 out of 10.
altRX is stronger on effectiveness (10.0 vs 9.0), user experience (8.0 vs 3.0) and support (7.0 vs 5.0).
Push Health is stronger on trust & safety (4.0 vs 3.5).
Value and accessibility are within half a point.
altRX
6.7/10
Push Health
5.6/10
Value25%
Effectiveness25%
User Experience15%
Trust & Safety15%
Accessibility10%
Support10%
FDA warning letters
The FDA sent altRX a warning letter dated June 8, 2026 (letter 728236), and it is still open.
Push Health has no FDA warning letter on record with us.
Features & Coverage
| Feature | altRX | Push Health |
|---|---|---|
| Starting Price | ✓$149/mo | $950/mo |
| Features | ✓8 features | 5 features |
| States Available | Not disclosed | Not disclosed |
| Compounded | ✓ Yes | — |
| Brand Name | ✓ Yes | ✓ Yes |
| FSA/HSA Accepted | — | — |
| FDA Warning Letters | 1 letter | ✓None |
About altRX
Compounded plans open at $149 for semaglutide and $249 for tirzepatide. Branded medication runs $1,149-$1,579, a figure that already contains the consult and the shipping. Every one of the four FDA-approved brands is stocked, Mounjaro, Ozempic, Wegovy and Zepbound, which no other entry in our directory matches. altRX works in both modalities, holds LegitScript certification, and prints the FDA compounded-medication disclaimer.
Read our full altRX review →About Push Health
A 55,000+ pharmacy network sits behind Push Health, which writes brand-name GLP-1 prescriptions, Mounjaro, Zepbound, and Ozempic, and routes them through it. The platform is a large US telehealth operation and holds LegitScript certification.
Read our full Push Health review →Pros & Cons
altRX
What we like
- Tirzepatide costs $1249 a month, close to the $1249 median for brand-name tirzepatide across the sellers we compare
- Shows its price before the medical questionnaire, so you can compare it without handing over health information
- The monthly price includes the medication, clinician visits and shipping
Watch-outs
- Semaglutide costs $1149 a month, 16% above the $990 median for brand-name semaglutide across the sellers we compare
- Confirm it serves your state before you start the intake
- Ask which pharmacy fills the prescription before you pay, so you can check its license
- The FDA has issued altRX a warning letter. Read what it alleges: a letter flags a problem but does not by itself rule a seller out
- Its semaglutide and tirzepatide are compounded rather than FDA-approved, so they have not been reviewed by the agency for safety, effectiveness or manufacturing quality
Push Health
What we like
- Semaglutide costs $950 a month, close to the $990 median for brand-name semaglutide across the sellers we compare
- We found no FDA warning letters issued to Push Health
Watch-outs
- You only see a price after finishing the medical intake, so you cannot compare costs before sharing health information
- Confirm it serves your state before you start the intake
- Ask which pharmacy fills the prescription before you pay, so you can check its license
Our Verdict
altRX wins this one, 6.7 to 5.6, above all for semaglutide from $1149/month. It also costs $801 less each month than Push Health. Push Health fits better if semaglutide from $950/month is your priority.
Choose altRX if…
You want semaglutide from $1149/month and an opening price near $149 a month.
Choose Push Health if…
You want semaglutide from $950/month and an opening price near $950 a month.
Ready to start? GLP-1 providers we have vetted
Telehealth providers, vetted by us, prescribing GLP-1 online.
Vetted by our editors · no insurance required
Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more
Sesame Care
Oral orforglipron alongside the injectables
From $59/mo
Get started →Collective
Flat any-dose pricing, if you can absorb a $199 annual membership on top
From $59/mo
Get started →Found
Tirzepatide at $169/month, 37% below the typical price
From $149/mo
Get started →altRX vs Push Health: FAQ
Close alternatives to altRX and Push Health
- altRX vs Gala
- altRX vs Sprout Health
- altRX vs Aquivia Health
- altRX vs Vytora Health
- Push Health vs JumpstartMD
- Push Health vs Marek Health
Or see the full category ranking.
Novo Nordisk A/S owns the Wegovy®, Ozempic® and Rybelsus® marks; Eli Lilly and Company owns Mounjaro® and Zepbound®. Every other product name and mark on this page belongs to whoever owns it. No pharmaceutical manufacturer is affiliated with GLP Watchdog. See trademark disclaimer.